Serbia extends drug company Galenika tender
Serbia extended its tender for the Galenika AD drug company for a fourth time, giving a unit of Canada’s Valeant Pharmaceuticals International Inc until June 14 to file a bid, the Finance Ministry said on its website. The government first called for bidders on Jan. 15, seeking a partner among drugmakers with operating revenue of at least €200 million ($$259.5 million) in 2011. Galenika cut its 2012 loss to RSD 5.6 billion ($65.2 million) from RSD 13.5 billion a year earlier.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.